BMO’s Seigerman on Pfizer-Metsera deal: Bullish as we’ve waited on Pfizer’s foray into obesity

Evan Seigerman, BMO Capital Markets head of healthcare research, joins ‘The Exchange’ to discuss Pfizer’s obesity drug prospects, competitors and much more.